BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 7915306)

  • 1. Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1.
    Rigaud M; Pollack H; Leibovitz E; Kim M; Persaud D; Kaul A; Lawrence R; John DD; Borkowsky W; Krasinski K
    J Pediatr; 1994 Sep; 125(3):476-80. PubMed ID: 7915306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group.
    Thea DM; Lambert G; Weedon J; Matheson PB; Abrams EJ; Bamji M; Straus WL; Thomas PA; Krasinski K; Heagarty M
    Pediatrics; 1996 Jan; 97(1):59-64. PubMed ID: 8545225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. National Pediatric and Family HIV Resource Center and National Center for Infectious Diseases, Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 1995 Apr; 44(RR-4):1-11. PubMed ID: 7565543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
    Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
    JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
    Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
    N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting risk of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected children.
    Rutstein RM
    Am J Dis Child; 1991 Aug; 145(8):922-4. PubMed ID: 1677526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumocystis carinii severe pneumonia among human immunodeficiency virus-infected children in Thailand: the effect of a primary prophylaxis strategy.
    Chokephaibulkit K; Wanachiwanawin D; Chearskul S; Wanprapa N; Unganont K; Tantinikorn W; Udompunthurak S
    Pediatr Infect Dis J; 1999 Feb; 18(2):147-52. PubMed ID: 10048687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.
    Schneider MM; Hoepelman AI; Eeftinck Schattenkerk JK; Nielsen TL; van der Graaf Y; Frissen JP; van der Ende IM; Kolsters AF; Borleffs JC
    N Engl J Med; 1992 Dec; 327(26):1836-41. PubMed ID: 1360145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
    Chaisson RE; Keruly J; Richman DD; Moore RD
    Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Multicenter AIDS Cohort Study.
    Graham NM; Zeger SL; Park LP; Phair JP; Detels R; Vermund SH; Ho M; Saah AJ
    Lancet; 1991 Aug; 338(8762):265-9. PubMed ID: 1677108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trimethoprim-sulfamethoxazole oral desensitization in hemophiliacs infected with human immunodeficiency virus with a history of hypersensitivity reactions.
    Kletzel M; Beck S; Elser J; Shock N; Burks W
    Am J Dis Child; 1991 Dec; 145(12):1428-9. PubMed ID: 1688295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
    Hoover DR; Saah AJ; Bacellar H; Phair J; Detels R; Anderson R; Kaslow RA
    N Engl J Med; 1993 Dec; 329(26):1922-6. PubMed ID: 7902536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and laboratory correlates of Pneumocystis carinii pneumonia in children infected with HIV.
    Connor E; Bagarazzi M; McSherry G; Holland B; Boland M; Denny T; Oleske J
    JAMA; 1991 Apr; 265(13):1693-7. PubMed ID: 1672168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
    Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
    N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of secondary prophylaxis for Pneumocystis pneumonia in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy.
    Esposito S; Bojanin J; Porta A; Cesati L; Gualtieri L; Principi N
    Pediatr Infect Dis J; 2005 Dec; 24(12):1117-20. PubMed ID: 16371882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumocystis carinii pneumonia in human immunodeficiency virus-infected infants and children.
    Goodwin SD
    Pharmacotherapy; 1993; 13(6):640-6. PubMed ID: 8302691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating a new strategy for prophylaxis to prevent Pneumocystis carinii pneumonia in HIV-exposed infants in Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group.
    Chokephaibulkit K; Chuachoowong R; Chotpitayasunondh T; Chearskul S; Vanprapar N; Waranawat N; Mock P; Shaffer N; Simonds RJ
    AIDS; 2000 Jul; 14(11):1563-9. PubMed ID: 10983643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus.
    MMWR Recomm Rep; 1991 Mar; 40(RR-2):1-13. PubMed ID: 1672036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumocystis carinii pneumonia prophylaxis and early clinical manifestations of severe perinatal human immunodeficiency virus type 1 infection. Northern California Pediatric HIV Consortium.
    Maldonado YA; Araneta RG; Hersh AL
    Pediatr Infect Dis J; 1998 May; 17(5):398-402. PubMed ID: 9613653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.